Merus to Present at Upcoming Investor Conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming investor conference participation.

The company's President and CEO, Bill Lundberg, M.D., will present at two major healthcare investment events:

• TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 9:10 a.m. ET
• Leerink Partners Global Healthcare Conference on Monday, March 10 at 11:20 a.m. ET

Webcasts of both presentations will be available live on the Investors page of the Merus website, with archived recordings accessible for a time after each event. The announcement comes as Merus continues to advance its portfolio of novel cancer therapeutics.

Positive

• Merus is actively engaging with investors through participation in prestigious healthcare conferences
• The company continues to advance its innovative oncology pipeline featuring proprietary antibody platforms
• Merus demonstrates transparency by providing public access to their investor presentations
• The company's leadership is directly involved in investor relations with the CEO presenting at conferences

Negative

• The press release doesn't provide specific updates on clinical progress or pipeline developments
• No financial information or business updates were included in the announcement
• The announcement lacks details about specific therapeutic candidates in development

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics^®, Triclonics^® and ADClonics^®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

• TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET
  

• Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET
  

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.

Multiclonics^®, Biclonics^®, Triclonics^® and ADClonics^® are registered trademarks of Merus N.V.

FAQ

When will Merus (MRUS) present at the TD Cowen Annual Health Care Conference in 2025?

Merus (MRUS) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 9:10 a.m. ET, as announced in their February 25 press release.

What conferences will Merus (MRUS) attend in March 2025?

In March 2025, Merus (MRUS) will attend two investor conferences: the TD Cowen 45th Annual Health Care Conference on March 4 and the Leerink Partners Global Healthcare Conference on March 10.

How can investors access Merus (MRUS) conference presentations in March 2025?

Investors can access Merus (MRUS) conference presentations via webcasts available on the Investors page of the company's website. The presentations will be available live and archived for a time after each event.

What type of therapeutic products is Merus (MRUS) developing according to their February 2025 announcement?

According to their February 2025 announcement, Merus (MRUS) is developing innovative, full-length multispecific antibodies and antibody drug conjugates, specifically their proprietary Biclonics®, Triclonics® and ADClonics® platforms for oncology applications.

Who will represent Merus (MRUS) at the March 2025 investor conferences?

Bill Lundberg, M.D., who serves as President and Chief Executive Officer of Merus (MRUS), will represent the company at both investor conferences in March 2025.